Loading
Amphastar Pharmaceuticals, Inc. Stock: price and insider trades · United States
Amphastar Pharmaceuticals, Inc.: what insiders have been doing
Amphastar Pharmaceuticals, Inc. belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). Between 18 October 2025 and 18 October 2026, 15 insiders published 41 filings.
Only sales appear on the open market, 6 sales in all totalling €560k, filed by 3 insiders. One trade stands out by size: a sale of €208k from Zhou Rong, disclosed on 17 September 2026, or 0.022% of market capitalisation.
With 41 filings in twelve months, the company is more active than the median of 22 filings across the 5,458 companies we follow on the same exchange. Since 2016, the database holds no purchases and 79 sales by insiders of the company. The 10-K for the year ended 31 December 2025 shows 719.9 m USD of revenue and 98.1 m USD of net income.
Filings reach the SEC (Form 4) feed a median of 2 days after the trade. For comparison, the SEC allows two business days to file a Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
Elsewhere in the same sector, our signals recently picked up insider purchases at Anixa Biosciences Inc and Vivos Inc. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
293
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€17M
79 ops. · all time
Who traded when
BuySalePetersen Floyd F.10 sales
Richard K. Prins2 sales
Rong Zhou2 sales
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 3,567 of 24,148 companies
70.1
score / 100
Value79
Quality62
FCF yld11%
Earn yld8.9%
EV/EBITDA8.3x
ROE10%
Gross mgn49%
Net mgn14%
Debt/EBITDA3.1x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$25.87
Analyst consensus
6 analysts3.14/5
US$20.00Target US$22.50(-13%)US$30.00
Income statement
RevenueUS$719.9M
Gross profitUS$356.1M49% margin
EBITDAUS$212.3M29% margin
Net incomeUS$98.1M10.8% margin
Valuation
PER (trailing)15.3x
PER (forward)8.1x
P/Book1.4x
Beta0.90
Balance sheet & cash
Market capUS$1.1B
Total debtUS$656M
Free Cash FlowUS$119M
Debt / Equity90%
Profitability & ownership
ROE10.3%
ROA5.1%
% insiders30.8%
% institutions68.3%
Last declaration on 21 September 2026
Declarations293 total
4,139 shares@ US$25.000.0097% mcap3.0% of flowCommonSEC144:0001969223-26-001034
47,101 shares@ US$21.000.087% mcap100.0% of flowCommon StockSEC144:0001969223-26-000926
7,973 shares@ US$20.300.014% mcap6.0% of flowCommon StockSEC:0001047579-26-000005:0
7,973 shares@ US$20.310.014% mcap100.0% of flowCommon StockSEC144:0001969223-26-000880
5,053 shares@ US$19.790.0089% mcap2.3% of flowCommon StockSEC:0001263136-26-000012:0
8,180 shares@ US$22.480.016% mcap4.3% of flowCommonSEC144:0001969223-26-000860
7,886 shares0Common StockSEC:0002141303-26-000005:0
1,500 shares0Common StockSEC:0001047579-26-000003:0
769 shares@ US$18.450.0016% mcap1.9% of flowCommon StockSEC:0001379941-26-000003:1
8,143 shares0Common StockSEC:0001033511-26-000003:0
8,143 shares0Common StockSEC:0001047579-26-000003:1
8,143 shares0Common StockSEC:0001379941-26-000003:0
8,143 shares0Common StockSEC:0001611283-26-000003:0
8,143 shares0Common StockSEC:0001866024-26-000003:0
8,143 shares0Common StockSEC:0002075974-26-000003:0
1,033 shares@ US$18.180.6% of flowCommon StockSEC:0001743927-26-000010:0
9,784 shares@ US$18.180.8% of flowCommon StockSEC:0000889740-26-000007:0
1,973 shares@ US$18.180.8% of flowCommon StockSEC:0001263136-26-000010:0
35,450 shares0Common StockSEC:0001743927-26-000008:0
58,693 shares0Common StockSEC:0001263136-26-000008:0
180,504 shares0Common StockSEC:0000889740-26-000005:0
25 of 293 declarations
About Amphastar Pharmaceuticals, Inc.
Amphastar Pharmaceuticals, Inc. (ticker: AMPH) is a U.S.-listed biopharmaceutical company traded on the NASDAQ market in the United States. Headquartered in Rancho Cucamonga, California, Amphastar describes itself as an integrated pharmaceutical company focused on developing, manufacturing, and commercializing technically challenging injectable, intranasal, and inhalation products, as well as active pharmaceutical ingredients (APIs). The company was incorporated in California in 1996 and has since expanded through acquisitions and internal platform development. ([amphastar.com](https://www.amphastar.com/about-us.html?utm_source=openai))
From an equity-analysis perspective, Amphastar’s business model combines an established commercial base with a pipeline designed to deepen its presence in specialized generics and biologics. The company sells more than 25 prescription products plus one over-the-counter product, Primatene MIST®, and its largest revenue contributors currently include BAQSIMI® glucagon nasal powder, Primatene MIST®, glucagon, epinephrine, and lidocaine. Management also highlights development programs spanning ANDAs, BLAs, and biosimilar insulin candidates, which positions Amphastar as more than a traditional commodity-generic manufacturer: it is pursuing a higher-complexity product mix with stronger barriers to entry. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1297184/000129718426000009/amph-20251231x10k.htm?utm_source=openai))
Read moreShow less
Amphastar’s competitive edge comes from manufacturing complexity and formulation expertise rather than scale alone. The company emphasizes expertise in sterile injectables, emergency medicines, and specialty delivery formats, areas where regulatory compliance, process control, and supply reliability matter greatly. It also states that it operates five manufacturing facilities across the United States, China, and Europe, along with an advanced research center, while all finished products are manufactured in the United States. That footprint supports quality, redundancy, and customer trust, but the company remains exposed to pricing pressure in mature generics and to competition in key hospital-oriented products. ([amphastar.com](https://www.amphastar.com/about-us.html?utm_source=openai))
Recent developments have been important for the investment case. Amphastar’s BAQSIMI® franchise was strengthened by the 2023 acquisition of the product, and in early 2025 the company assumed full global distribution responsibilities, helping revenue recognition and giving Amphastar greater control over the brand’s commercial rollout. The company also continued to refresh its portfolio with launches such as albuterol in 2024 and iron sucrose in 2025. In July 2025, Amphastar announced a multi-year expansion of U.S. manufacturing capacity at its Rancho Cucamonga headquarters, which it characterized as the largest domestic infrastructure investment in its history. These actions suggest a clear strategic focus on supply-chain control, capacity expansion, and strengthening its specialty-product franchise. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1297184/000129718426000009/amph-20251231x10k.htm?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
